NasdaqGS:CGONBiotechs
What CG Oncology (CGON)'s Pivotal BOND-003 Phase 3 Data Means For Shareholders
CG Oncology recently reported that The Lancet Oncology published pivotal Phase 3 BOND-003 Cohort C data showing cretostimogene grenadenorepvec monotherapy achieved statistically significant complete responses with durable outcomes and a favorable safety profile in high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
The trial results suggest cretostimogene could fit smoothly into everyday urology practice because it avoids operating room time, anesthesia...